Ironwood Pharmaceuticals, Inc. $IRWD Shares Bought by Inspire Investing LLC

Inspire Investing LLC lifted its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 159.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 231,825 shares of the biotechnology company’s stock after buying an additional 142,574 shares during the quarter. Inspire Investing LLC owned approximately 0.14% of Ironwood Pharmaceuticals worth $341,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in IRWD. McAdam LLC purchased a new stake in Ironwood Pharmaceuticals in the 1st quarter worth $40,000. Simplicity Wealth LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the first quarter worth about $45,000. Dynamic Technology Lab Private Ltd purchased a new position in Ironwood Pharmaceuticals in the 1st quarter valued at about $57,000. Y Intercept Hong Kong Ltd lifted its stake in Ironwood Pharmaceuticals by 162.6% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 39,782 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 24,635 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in Ironwood Pharmaceuticals during the 4th quarter worth approximately $59,000.

Ironwood Pharmaceuticals Stock Performance

NASDAQ:IRWD opened at $1.28 on Thursday. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $0.53 and a fifty-two week high of $5.13. The company has a 50 day moving average price of $1.01 and a 200 day moving average price of $0.96. The stock has a market capitalization of $207.91 million, a P/E ratio of -25.59 and a beta of 0.33.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%.The company had revenue of $85.24 million for the quarter, compared to analysts’ expectations of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IRWD has been the topic of several research reports. Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 5th. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. One analyst has rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $4.94.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.